Mounjaro™ (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Tirzepatide: Use in Patients With Gastroparesis

Tirzepatide has not been studied in people with delayed gastric emptying.

US_cFAQ_TZP320_USE_IN_PATIENTS_WITH_GASTROPARESIS
cFAQ
cFAQ
US_cFAQ_TZP320_USE_IN_PATIENTS_WITH_GASTROPARESIS
en-US

Detailed Information

There is no information on the use of tirzepatide in people with gastroparesis because patients were excluded from tirzepatide clinical trials if they had a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction).

Date of Last Review: February 05, 2021


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical